Paradigm Signs Contract With UnitedHealthcare for Cancer Testing Service

Contract Will Help Expand Coverage for Paradigm Cancer Diagnostic (PCDx™) to Oncologists Nationwide

Jan 21, 2016, 10:53 ET from Paradigm

ANN ARBOR, Mich. and PHOENIX, Jan. 21, 2016 /PRNewswire-USNewswire/ -- Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing testing for cancer patients today announced that it has entered into a contractual agreement with UnitedHealthcare for coverage of PCDx.

PCDx™ is a Next-Generation Sequencing (NGS) based diagnostic test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a patient's tumor's DNA, RNA & Protein.

Dr. Robert Penny, MD, PhD, CEO of Paradigm, stated, "We continue to make excellent progress in our discussions with provider networks to ensure our best-in-class NGS test is available to the millions of Americans who are suffering with cancer.  With this contract, millions of patients and their treating clinicians will have access to our leading oncology testing service and make possible more informed and individually tailored treatment strategies."


Paradigm is a molecular information corporation established to bring cutting-edge diagnostics to cancer patients and industry by providing information about the genomic makeup of the patient's cancer and potential therapies based on the specific characterization of the patient's tumor that can impact the patient's course of treatment. Paradigm's Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit Follow us on Twitter @Paradigm_DX

Logo -


SOURCE Paradigm